摘要
目的:门冬胰岛素30注射液三种治疗方案的疗效与成本-效果评价。方法:对2010年1月1日至2010年12月31日收集的2型糖尿病135例采用门冬胰岛素30注射液三种治疗方案,A组(早晚皮下注射门冬胰岛素30注射液),B组(早中晚皮下注射门冬胰岛素30注射液),C组(早晚皮下注射门冬胰岛素30注射液,中餐嚼服阿卡波糖)分别治疗半年。结果:空腹血糖总有效率分别为84.4%、86.7%和91.1%,餐后2h血糖分别为91.1%、91.1%和88.9%,糖化血红蛋白总有效率分别为75.6%、80.0%和77.8%。结论:三种治疗方案都有较高疗效,疗效无统计学差异,C组的成本要比A组、B组分别节约104.62元和626.80元,C组的成本-效果比低于另外两组,效价性高,更具有临床推广价值。
To compare the clinical therapeutic effects and costeffectiveness of Insulin Aspart 30 Injection （NovoMix30FlexPen） among different therapeutic regimens for diabetic patients. METHODS： A retrospective study was conducted in which a total of 135 eases with type 2 diabetes mellitus were divided into 3 groups by random（A： NovoMix30FlexPen for morning or night for 6 months; B. NovoMix30FlexPen prior three meals for 6 months; C： NovoMix30FlexPen for morning or night ＋ Acarbose Tablets for 6 months）. RESULTS： The effective rates of FBG were 84.4% in Group A versus 86. 7% in Group B and 91. l%in Group C （P）0.05）, the effective rates of 91.1%, 91.1%and 88.90%, and rates of HbAlc were 75.6%, 80. PBG2h were the effective ,77.8% respectively. CONCLUSION： Blood sugar /eve/ can be controlled to an ideal level through the three treatment schemes; while Group C is better considering the costeffectiveness ratios, and it hasthe clinical value of noDularization.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2011年第12期1406-1409,共4页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
吴江市社会发展计划
软科学研究项目(WS201008)
